论文部分内容阅读
《美国医学会杂志》正常运营需要的巨额费用,迫使理事会为获取赞助而放弃医学伦理规范,开始刊登专利药品和秘密制剂广告。这种置医学伦理于不顾的政策,遭致了医学会内部改革派的诸多质疑和批评。然而,困厄于经济与伦理之间的美国医学会,常常在允许和禁止刊登专利药品广告上摇摆不定。20世纪以来,诸多因素的合力促成了美国医学会力量的不断壮大,它最终获得了掌控其广告政策的财政资源和话语权力,医学伦理的真正践履成为可能。而1905年药学和化学委员会等相关机构的增设,一系列改革宣传、揭发黑幕和游说医学界工作的相继展开,美国医学会寻求到了经济利益和医学伦理两者和谐共生的支点,实现了药品广告政策的制度化。这不仅增进了医生的职业认同感,而且部分地弥补了联邦政府药品广告管理制度上的缺失。
The huge costs required for the normal operation of the Journal of the American Medical Association have compelled the board to abandon medical ethics for sponsorship and start advertising on proprietary drugs and clandestine preparations. This policy of disregarding medical ethics has caused many questions and criticisms from the reformists within the medical society. However, the American Medical Association, distressed between economics and ethics, often waveringly allows and prohibits the publication of proprietary pharmaceutical advertisements. Since the 20th century, the combination of many factors has contributed to the growing strength of the American Medical Association. It eventually gained the financial resources and the power of discourse to control its advertising policies. The real fulfillment of medical ethics is possible. The 1905 Pharmaceutical and Chemical Committee and other related agencies to create a series of reform and advocacy to expose the work of the shady and lobbying medical community have been started, the American Medical Association to seek the economic interests and medical ethics both symbiosis fulcrum, the realization of drug advertising Institutionalization of policies. This not only enhances doctor’s professional identity, but also partially compensates for the lack of federal drug administration system.